ReviewAnnals of intensive care2023

Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients.

François Barbier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.